Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified (DBCOND0114149)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04074746	Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas	AFM-13 Acimtamig Cyclophosphamide Fludarabine	treatment	1 / 2	active_not_recruiting
NCT04795869	Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma	Brentuximab vedotin Pembrolizumab	treatment	2	withdrawn
NCT03598998	Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas	Pembrolizumab Pralatrexate	treatment	1 / 2	active_not_recruiting
NCT01590732	Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma	Beta-D-Glucose Carboplatin Cyclophosphamide Etoposide Ifosfamide Romidepsin	treatment	1	completed